What determines the optimal urinary diversion?
“Ultimately, there is no ‘right choice’ when it comes to urinary diversion,” writes Anne K. Schuckman, MD.
Related Articles
Join and Save – AUA Annual Meeting
Become an AUA member and SAVE up to $886 on Annual Meeting registration!
Carl A. Olsson, MD: A True Legend and Friend | Urology Practice
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
What Is Needed to Support Nonurban Urology in the United States? Perspectives From Urologists in Rural and Underresourced Areas | Urology Practice
Introduction:Twenty percent of Americans live in nonurban areas, and the challenges in providing high-quality health care in rural areas are well described. These challenges are…
BWL plus ultrasonic propulsion shows safety, efficacy for small renal stones
Overall, 71% of patients had no fragment greater than 2 mm following treatment.
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space.
Exploring Recent Developments in the Treatment of Prostate Cancer
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma – Uroweb
The European Association of Urology (EAU) NMIBC Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management…
Polygenic Risk Score May Have Clinical Utility for Prostate Cancer Screening
Current prostate cancer screening methods may not identify all patients requiring cancer treatment.
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD.
Residual Cancer After Neoadjuvant Tx Predicts High-Risk Prostate Cancer Outcomes
Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.